Central Nervous System (CNS) Lymphoma Market Report 2026

Central Nervous System (CNS) Lymphoma Market Overview

• Central Nervous System (CNS) Lymphoma market size has reached to $1.53 billion in 2025 • Expected to grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: The Role Of Mental Health Issues In Shaping The Market • Market Trend: FDA Grants Orphan Drug Status To Tirabrutinib • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Central Nervous System (CNS) Lymphoma Market?

Central nervous system (CNS) lymphoma is a rare and aggressive type of lymphoma that originates in the brain or spinal cord. Its treatment aims to target and shrink cancerous cells in the CNS, alleviate symptoms, and improve survival rates through a combination of medications, targeted therapies, and focused high-energy treatments. The main drugs for the central nervous system (CNS) lymphoma market are monoclonal antibodies, chemotherapeutic agents, and corticosteroids. Monoclonal antibodies are lab-made proteins that mimic the immune system's ability to detect and neutralize specific targets, such as viruses, cancer cells, or inflammatory molecules. These treatments are administered through various approaches, including chemotherapy, radiation therapy, steroid therapy, and targeted therapy. The market also caters to different applications, such as hospitals, clinics, ambulatory surgical services, and other applications.

What Is The Central Nervous System (CNS) Lymphoma Market Growth Forecast?

The central nervous system (cns) lymphoma market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investments in targeted oncology drugs, rising adoption of personalized cancer treatment, expansion of biomarker-driven therapy selection, growing focus on rare cancer research, increasing clinical trial activity in cns malignancies. Major trends in the forecast period include increasing adoption of targeted immunotherapy treatments, rising use of monoclonal antibody-based therapies, growing integration of precision diagnostics in treatment planning, expansion of combination therapy approaches, enhanced focus on early disease detection.

Global Central Nervous System (CNS) Lymphoma Market Segmentation

1) By Class Of Drugs: Monoclonal Antibodies, Chemotherapeutic Agents, Corticosteroids 2) By Treatment: Chemotherapy, Radiation Therapy, Steroid Therapy, Targeted Therapy 3) By Application: Hospitals, Clinics, Ambulatory Surgical Services, Other Applications Subsegments: 1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies, Anti-PD-1 Monoclonal Antibodies, Other Targeted Monoclonal Antibodies 2) By Chemotherapeutic Agents: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors 3) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

What Are The Drivers Of The Central Nervous System (CNS) Lymphoma Market?

The increasing incidences of psychological disorders are expected to propel the growth of the central nervous system (CNS) lymphoma market going forward. Psychological disorders are mental health conditions that disrupt thoughts, emotions, or behaviors, causing distress or impairment. The rise in psychological disorders is driven by stress, social isolation, economic pressures, genetics, substance abuse, and digital overuse. Central nervous system (CNS) lymphoma advances neuro-oncology research, improving understanding of brain inflammation, immune interactions, and the blood-brain barrier, which aids in developing better treatments for both cancer and psychological disorders. For instance, in November 2023, according to the National Health Service, a UK-based government department, in 2023, approximately one in five individuals aged 8 to 25 years were estimated to have a probable mental disorder, affecting 20.3% of 8 to 16-year-olds, 23.3% of 17 to 19-year-olds, and 21.7% of 20 to 25-year-olds. Therefore, increasing incidents of psychological disorders are driving growth in the central nervous system (CNS) lymphoma industry. The rising prevalence of neurological disorders is expected to propel the growth of the central nervous system (CNS) lymphoma market going forward. Neurological disorders refer to any conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. The increasing prevalence of neurological disorders can be attributed to various factors, including genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Central nervous system (CNS) lymphoma enhances research on brain function, immune response, and neuroinflammation, leading to improved diagnostics and treatments that also benefit patients with neurological disorders. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, by 2060, nearly 14 million adults are projected to have Alzheimer's disease in the United States. Therefore, the rising prevalence of neurological disorders is expected to drive the growth of the central nervous system (CNS) lymphoma industry.

Key Players In The Global Central Nervous System (CNS) Lymphoma Market

Major companies operating in the central nervous system (cns) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Incyte Corporation, Kazia Therapeutics Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc., Bristol‑Myers Squibb Company, Johnson & Johnson, AstraZeneca plc, Pfizer Inc, BeiGene Ltd, Bayer AG, Spectrum Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Kyowa Kirin Co Ltd, Celltrion Inc, Regeneron Pharmaceuticals Inc, BioNTech SE, PIQUR Therapeutics AG, Curis Inc, TG Therapeutics Inc, Oncoceutics Inc, XEME Biopharma LLC

Global Central Nervous System (CNS) Lymphoma Market Trends and Insights

Major companies operating in the central nervous system (CNS) lymphoma market are focusing on developing innovative therapies such as Tirabrutinib for the treatment of primary central nervous system (CNS) lymphoma. Tirabrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of B-cell malignancies, including primary central nervous system lymphoma (PCNSL), by targeting pathways critical to cancer cell survival and proliferation. For instance, in March 2023, ONO Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tirabrutinib (ONO-4059) for treating primary central nervous system lymphoma (PCNSL). This is currently under investigation in the phase 2 PROSPECT study (NCT04947319), tirabrutinib is a potent, selective BTK inhibitor targeting B-cell proliferation and survival. Tirabrutinib regulates cellular proliferation and activation through the B-cell receptor, enabling survival, differentiation, and clonal expansion of B-cells.

Regional Outlook

North America was the largest region in the central nervous system (CNS) lymphoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Central Nervous System (CNS) Lymphoma Market?

The central nervous system (CNS) lymphoma market consists of revenues earned by entities by providing services such as diagnostic service, therapy services, and supportive and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system (CNS) lymphoma market also includes sales of drugs, therapy equipment, supportive therapies, and surgical instruments & tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Central Nervous System (CNS) Lymphoma Market Report 2026?

The central nervous system (cns) lymphoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system (cns) lymphoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.